ADHD Drugs Market: Growth, Future Prospects, and Competitive Analysis, 2023 – 2030

Market Definition

The ADHD drugs market refers to the market for medications used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD). ADHD is a neurodevelopmental disorder that affects both children and adults, and is characterized by symptoms such as impulsivity, hyperactivity, and inattention. ADHD drugs can help manage these symptoms and improve the quality of life of patients.

There are several types of ADHD drugs, including stimulants such as methylphenidate and amphetamines, non-stimulants such as atomoxetine and guanfacine, and other medications such as clonidine and bupropion. These drugs work by affecting the levels of certain chemicals in the brain, such as dopamine and norepinephrine.

Key Market Drivers and Restraints

Rising awareness regarding ADHD drugs among physicians, patients, and other healthcare providers is expected to drive the growth of the global ADHD Drugs market. Also, increasing number of clinical trials, and rising awareness regarding diagnosis and treatment of the condition is projected to fuel the growth of the global market over the forecast period.

However, under diagnosis of ADHD due to existence of comorbid conditions in children, low availability and lack of awareness of non-stimulant drugs to treat ADHD in various regions are expected to hamper the global ADHD drugs market.

Impact of COVID 19

The ADHD drug market will show considerable growth on the back of the global pandemic. As a result of the COVID-19 outburst, healthcare organizations have deprioritized the best part of non-essential medical treatments. Furthermore, with supply chain disruptions and delayed production lines, players are leveraging the demand for medicines, and are difficult to dispatch them to stores that are running out of necessary medicines.

North America to Dominate the global ADHD Drugs Market

The global ADHD Drugs Market covers the six regions, namely Europe, North America, Asia Pacific, Latin America (LATAM), Middle East and Africa, including all the key economies in these regions. North America market is dominated the global market and accounted for more than 62.0% of the total market. This is attributed to the large volume of drug prescriptions, increasing product launches, and rising collaboration among players to enhance market penetration.

Global ADHD Drugs Market is led by the Adult (Aged 18 and above)

Adult (Aged 18 and above), and Children, are the key age-group in the ADHD Drugs Market. In 2020, Adult (Aged 18 and above) segment is accounted for the largest share of ADHD Drugs Market. However, Children segment is anticipated to grow at the fastest CAGR during the forecast period.

Stimulant would continue to dominate the global ADHD Drugs Market in terms of Drug Type

Stimulant and Non-stimulant are some of the major types of drug type. Stimulant segment accounted for the largest share in 2020 of the ADHD Drugs Market in 2020. Increasing demand for stimulant drugs due to their effectiveness in treating symptoms of attention-deficit disorder, government imitative for the use of stimulants, and ongoing clinical trials

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Southeast Asia
  • Rest of Southeast Asia
  • The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
  • Latin America
  • Brazil
  • Argentina
  • Rest of Latin America

Proceed To Buy

USD 2950
USD 3950

Report Detail

  • Status:Published
  • Report Code:NNRR 65
  • No. of Pages:161
  • Published DateJune 2023
  • Category:Pharmaceutical
  • Delivery Timeline:48 hrs

Customized

  • => Region Level Market Share
  • => Import Export Analysis
  • => Additional Company Profiles
  • => Region Specific Market Dynamics
  • => Production Analysis
  • => Additional Countries (Apart From Mentioned Countries)
  • => Country/Region-specific Report